Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China

Non-small cell lung cancer (NSCLC), one of the deadliest types of cancers worldwide, has been the target of immunotherapy due to its high immune antigenicity. With the addition of immune-checkpoint inhibitors (ICIs), including anti-PD-1/PD-L1 antibodies, as an indispensable and powerful regimen for...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuno, Takaaki, Katsuya, Yuki, Sato, Jun, Koyama, Takafumi, Shimizu, Toshio, Yamamoto, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459234/
https://www.ncbi.nlm.nih.gov/pubmed/36091105
http://dx.doi.org/10.3389/fonc.2022.925938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459234/
https://www.ncbi.nlm.nih.gov/pubmed/36091105
http://dx.doi.org/10.3389/fonc.2022.925938

Ejemplares similares